No Data
"Shuanghuanglian" pharmaceutical giant leader Cao Changcheng has passed away, and his son Cao Zhiming takes over fusen pharm.
Fusen pharm announced on November 4th that the Chairman of the Board of Directors, Cao Changcheng, passed away on October 31st.
Hong Kong stock concept tracking | The end of medical insurance negotiations is very encouraging for innovative drugs to be included in medical insurance at reasonable prices (with concept stocks)
The on-site negotiation and bidding stages for the adjustment of the national medical insurance pharmaceutical catalog in 2024 officially ended recently.
Fusen Pharmaceutical: Chairman Cao Changcheng Passes Away
Fusen Pharm (01652.HK): Cao Zhiming has been appointed as the chairman of the board of directors.
Grain Alliance reported on November 4th that Mr. Cao Changcheng, chairman of the board, executive director, chairman of the nomination committee, and member of the remuneration committee of Fusen Pharm (01652.HK), passed away on October 31, 2024. Effective November 4, 2024, Mr. Cao Zhiming, an executive director of the company, has been appointed as the chairman of the board of directors, chairman of the nomination committee, and member of the remuneration committee, to succeed the late Mr. Cao.
Is it the most 'rolled up' in history? The tenth batch of national procurement pharmaceutical catalog is officially announced, with up to 31 companies competing for a single variety.
①This afternoon, the National Pharmaceutical Centralized Procurement Office officially announced the tenth batch of national procurement pharmaceutical catalog, with a total of 263 specifications and 62 varieties; ②Many industry insiders believe that the tenth batch of national procurement will be the largest and most competitive national procurement in history.
Zheshang Securities: Continuous realization of technological innovation upgrades driving the continuous improvement of performance expectations for innovative drugs and industry chains.
As the innovative drugs industry chain enters the commercialization realization period driven purely by incremental growth, the scarcity of incremental prosperity in the pharmaceutical sector continues to rise, international competitiveness continues to improve, and there is still room for upward valuation.
No Data
No Data